ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apraglutide

Also written as “Apraglutide”, “FE203799 GLP-2 analogue” and “FE 203799”.

Its studies are mostly in Short Bowel Syndrome · Graft vs Host Disease · Renal Insufficiency, Chronic · Hodgkin Disease, led by 2 companies.

Drug pageApraglutide: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 22, 202012 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticalsits history only92 open or runningphase 3since Oct 22, 2020Oct 22, 2020Oct 30, 2027phase 3 · NCT05018286
GlyPharma Therapeutics30 open or runningphase 2since Nov 13, 2017Nov 13, 2017none ahead

Also a collaborator on its studies: PSI CRO.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of GlyPharma Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2017First studies: 3 phase 2 studiesFirst studyNCT03417765, NCT03415594, NCT03408132
  2. Dec 9, 2017Named apraglutideINNProposed as its International Nonproprietary Name in WHO's List 118 · before, FE 203799, FE203799

TargetBeta

GCG →read by rule
“A synthetic, long-acting glucagon-like peptide-2 (GLP-2) agonist, with intestinotrophic activity”NCIt, by rule

Studies

All 3 GlyPharma Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03408132Short Bowel Syndrome · Denmark2CompletedOct 28, 20198
NCT03415594Short Bowel Syndrome · Denmark2CompletedNov 21, 20198
NCT03417765Lymphoma2WithdrawnMar 31, 20190

How it is read

Names in the registry

  • “Apraglutide”, 8 entries
  • “FE203799 GLP-2 analogue”, 2 entries
  • “apraglutide”, 1 entry
  • “FE 203799”, 1 entry
  • “FE203799”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.